Pfizer Corporation

Flagship Pioneering Innovations Vi, LLC

Adam Reid Root

Lidia Mosyak

Edward Roland Lavallie

Madan Katragadda

Divya Mathur

Chew Shun Chang

Gurkan Guntas

Leslie Sydnor Johnson

Paul A Moore

Lioudmila Tchistiakova

William Brady

Anthony Coyle

Laird Bloom

Alexis Hiram Ramos

Kristen Park Hopson

Chad Michael May

Antonios O Aliprantis

Ryan Terrell Phennicie

Lana Dinic

Karin Alma Frieda Reif

Zachary Kohl Costello

The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

Antibodies specific for GUCY2c and uses thereof

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.

Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.

Bispecific heterodimeric diabodies and uses thereof

Growing community of inventors

Byfield, MA, United States of America

Adam Reid Root